title: Study of industrial microencapsulated ferrous sulfate by means of the prophylactic-preventive method to determine its bioavailability.
abstract: Radio-iron tests are frequently used to measure the bioavailability of different iron sources for food fortification. As the labeling procedures must be done under laboratory conditions, complementary studies should be carried out to evaluate the bioavailability of iron sources produced on an industrial scale. The iron bioavailability of SFE-171 (ferrous sulfate microencapsulated with phospholipids) was studied in previous reports using the compounds labeled with 59Fe and 55Fe; the results showed an iron bioavailability similar to that of ferrous sulfate. In the present work, the iron bioavailability of industrial SFE-171 was studied by the prophylactic-preventive method in rats using ferrous sulfate as the reference standard. Elemental iron powder was also studied by the same method for comparative purposes. The liver iron concentration of each animal was determined at the end of the experiment in order to evaluate the influence of each iron source on the liver iron stores. Relative biological values of 98 and 34% were found for SFE-171 and elemental iron powder, respectively, while the corresponding relative liver iron concentrations were 104 and 45%. The results provided by the prophylactic-preventive method show that the iron bioavailability of industrial SFE-171 is similar to that of ferrous sulfate; these results are also in agreement to those obtained with the radioactive compounds. We can conclude that the SFE-171 obtained by industrial procedures for massive use in iron food fortification has the same bioavailability as that of the SFE-171 produced and labeled under laboratory conditions.
authors.affiliation: Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. aelysion@huemul.ffyb.uba.ar
authors.forename: A E
authors.initials: AE
authors.lastname: Lysionek
authors.forename: M B
authors.initials: MB
authors.lastname: Zubillaga
authors.forename: M J
authors.initials: MJ
authors.lastname: Salgueiro
authors.forename: M I
authors.initials: MI
authors.lastname: Sarabia
authors.forename: R A
authors.initials: RA
authors.lastname: Caro
authors.forename: R
authors.initials: R
authors.lastname: Weill
authors.forename: J R
authors.initials: JR
authors.lastname: Boccio
mesh_terms: D000818:Animals; D001682:Biological Availability; D004339:Drug Compounding; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005527:Food, Fortified; D007408:Intestinal Absorption; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism*; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D008297:Male; D010743:Phospholipids; D051381:Rats; D017207:Rats, Sprague-Dawley; D012015:Reference Standards
chemical_list: D005296:Ferrous Compounds; D010743:Phospholipids; C020748:ferrous sulfate; D007501:Iron